entecavir + tenofovir disoproxil fumarate + tenofovir alafenamide + TMF + pegylated interferon alfa-2b

This is a multi-drug combination regimen comprising **entecavir**, **tenofovir disoproxil fumarate**, **tenofovir alafenamide**, **TMF** (tenofovir monophosphate fumarate, a prodrug of tenofovir), and **pegylated interferon alfa-2b**. Each component has a distinct but complementary mechanism of action, primarily targeting hepatitis B virus (HBV) replication and immune modulation. - **Entecavir** is a guanosine nucleoside analogue that inhibits HBV DNA polymerase, impairing viral replication. - **Tenofovir disoproxil fumarate** and **tenofovir alafenamide** are nucleotide reverse transcriptase inhibitors that act as adenosine monophosphate analogues, leading to chain termination during DNA synthesis by HBV reverse transcriptase. - **TMF (tenofovir monophosphate fumarate)** similarly acts as a prodrug of tenofovir, and is assumed to function through the same mechanism as other tenofovir formulations. - **Pegylated interferon alfa-2b** is a pegylated recombinant alpha interferon. It binds to type I interferon receptors, inducing antiviral, antiproliferative, and immunomodulatory activities via the JAK/STAT pathway. This combination aims to provide potent antiviral activity and immune system modulation, especially in cases of multi-drug resistant or treatment-refractory HBV infection. Although combination therapy involving nucleoside/nucleotide analogues with peginterferon alfa-2b is not a standard first-line approach, such regimens may be considered in complex or salvage scenarios.

Other names

REASON study treatment regimenentecavir + tenofovir alafenamide + tenofovir disoproxil fumarate + TMF + interferon